Robotics / news brief
Remedy Robotics raises $62 million for trials of its endovascular robot
- Event
- Published

Remedy Robotics raised a $62 million Series B led by DCVC. The company says the funding will support a planned University of California pivotal trial, work toward FDA approval and prototype N1 deployments. N1 combines robotics, imaging and machine learning for on-site, remote or autonomous procedures, but it remains investigational and is not available for sale or clinical use.
Why it matters
The round funds the costly transition from remote-procedure demonstrations to clinical evidence and regulatory review for robotic vascular intervention.
Sources
- Remedy Robotics Raises $62 Million Series B (external site)Remedy Robotics · primary source ·
- Remedy Robotics Raises $62M in Series B Funding (external site)FinSMEs · coverage ·